
32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation
Publication
, Conference
Segelov, E; Thavaneswaran, S; Waring, P; Desai, J; Mann, K; Elez, E; Chantrill, L; Pavlakis, N; Nott, L; Underhill, C; Khasraw, M; Wasan, H ...
Published in: European Journal of Cancer
September 2015
Duke Scholars
Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
September 2015
Volume
51
Start / End Page
S726 / S726
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Mann, K., Elez, E., … Shapiro, J. (2015). 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. In European Journal of Cancer (Vol. 51, pp. S726–S726). Elsevier BV. https://doi.org/10.1016/s0959-8049(15)30078-2
Segelov, E., S. Thavaneswaran, P. Waring, J. Desai, K. Mann, E. Elez, L. Chantrill, et al. “32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.” In European Journal of Cancer, 51:S726–S726. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(15)30078-2.
Segelov E, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, et al. 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. In: European Journal of Cancer. Elsevier BV; 2015. p. S726–S726.
Segelov, E., et al. “32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.” European Journal of Cancer, vol. 51, Elsevier BV, 2015, pp. S726–S726. Crossref, doi:10.1016/s0959-8049(15)30078-2.
Segelov E, Thavaneswaran S, Waring P, Desai J, Mann K, Elez E, Chantrill L, Pavlakis N, Nott L, Underhill C, Khasraw M, Wasan H, Ciardiello F, Jefford M, Joubert W, Haydon A, Karapetis C, Price T, Wilson K, Shapiro J. 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. European Journal of Cancer. Elsevier BV; 2015. p. S726–S726.

Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
September 2015
Volume
51
Start / End Page
S726 / S726
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis